Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 1:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 1,207 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: COVID Clear all
Terminated No phase listed Observational

Efficacy of COVID-19 Vaccination in Patients With Multiple Sclerosis Treated With Immune Modulating Medication

NCT04796584
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Analysis of cell-mediated and antibody-mediated immunity to SARS-CoV-2 virus
Other
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 3, 2023 · Synced Oct 20, 2026, 1:57 PM EDT
Completed Phase 3 Interventional Results available

ACTIV-6: COVID-19 Study of Repurposed Medications - Arm C (Fluticasone)

NCT05736874
View directory record Official record
Conditions
Covid19
Interventions
Fluticasone, Placebo
Drug · Other
Lead sponsor
Susanna Naggie, MD
Other
Eligibility
30 Years and older
Enrollment
1,407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
87
States / cities
Gilbert, Arizona • Mesa, Arizona • Peoria, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Oct 20, 2026, 1:57 PM EDT
Terminated Phase 2 Interventional

Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy

NCT04542993
View directory record Official record
Conditions
Covid19, SARS-CoV Infection
Interventions
Zinc Picolinate, Resveratrol, Zinc Picolinate Placebo, Resveratrol Placebo
Dietary Supplement
Lead sponsor
Swedish Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 29, 2022 · Synced Oct 20, 2026, 1:57 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Rutgers Pilot for Dental Health Care Worker SARS-CoV-2 Testing

NCT05607147
View directory record Official record
Conditions
SARS-CoV2 Infection
Interventions
Testing for SARS CoV2 Antigen and Antibody
Device
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 24, 2023 · Synced Oct 20, 2026, 1:57 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

COVID-19 Survivorship Registry

NCT04527315
View directory record Official record
Conditions
Covid19
Interventions
Questionnaires
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Oct 20, 2026, 1:57 PM EDT
Recruiting Not applicable Interventional

Percutaneous Electrical Nerve Field Stimulation (PENFS) in Patients With Post Concussion Syndrome (PCS)

NCT04978571
View directory record Official record
Conditions
Post-Concussion Syndrome, COVID Long-Haul, COVID-19
Interventions
percutaneous electrical nerve-field stimulation, PENFS, percutaneous electrical nerve-field stimulation, PENFS (sham device), percutaneous electrical nerve-field stimulation, PENFS (COVID active device)
Device
Lead sponsor
Children's Hospital of Orange County
Other
Eligibility
11 Years to 18 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 20, 2026, 1:57 PM EDT
Completed Phase 2 Interventional

Phase 2 Study of RSLV-132 in Subjects With Long COVID

NCT04944121
View directory record Official record
Conditions
Post-acute Corona Virus 19 (COVID-19) (Long COVID)
Interventions
RSLV-132, Sodium Chloride 0.9%
Drug
Lead sponsor
Resolve Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
5
States / cities
Mobile, Alabama • Coral Gables, Florida • Pompano Beach, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated May 29, 2024 · Synced Oct 20, 2026, 1:57 PM EDT
Completed No phase listed Observational

imPulse™ Una Full-spectrum, Over Clothing E-stethoscope

NCT04556149
View directory record Official record
Conditions
Corona Virus Infection, Coronavirus
Interventions
imPulse™ Una e-stethoscope, Philips Lumify Ultrasound System
Device
Lead sponsor
Level 42 AI, Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Oct 20, 2026, 1:57 PM EDT
Withdrawn Not applicable Interventional

Use of Technology and Telemedicine to Improve Quality of Care in COVID 19 Patients

NCT04480411
View directory record Official record
Conditions
Diagnoses Disease, Covid19
Interventions
Doctorgram Patient Kit
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 31, 2022 · Synced Oct 20, 2026, 1:57 PM EDT
Not yet recruiting Phase 2Phase 3 Interventional

A Multi-Center, Individually-Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Superiority Trial to Evaluate the Efficacy of the Combination of Maraviroc and Atorvastatin for the Treatment of Subjects With Long COVID

NCT06974084
View directory record Official record
Conditions
Long COVID
Interventions
Maraviroc (MVC), Atorvastatin, 10mg, 20mg, 40mg, Placebo, Maraviroc, Placebo, Atorvastatin
Drug
Lead sponsor
HealthBio, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 20, 2026, 1:57 PM EDT
Suspended No phase listed Observational Accepts healthy volunteers

Validation of HyperDetector for SARS-CoV-2

NCT05124496
View directory record Official record
Conditions
SARS-COV2 Infection
Interventions
Screening Device
Device
Lead sponsor
HyperSpectral APD
Industry
Eligibility
5 Years and older
Enrollment
10,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Alexandria, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 18, 2021 · Synced Oct 20, 2026, 1:57 PM EDT
Withdrawn Phase 4 Interventional

Hydroxychloroquine in SARS-CoV-2 (COVID-19) Pneumonia Trial

NCT04382625
View directory record Official record
Conditions
SARS-CoV-2 Pneumonia, COVID-19
Interventions
Hydroxychloroquine
Drug
Lead sponsor
Kootenai Health
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Coeur d'Alene, Idaho
Source: ClinicalTrials.gov public record
Updated Feb 5, 2021 · Synced Oct 20, 2026, 1:57 PM EDT
Completed Phase 2 Interventional

A Decentralized, Randomized Phase 2 Efficacy and Safety Study of Nirmatrelvir/Ritonavir in Adults with Long COVID.

NCT05668091
View directory record Official record
Conditions
Long COVID
Interventions
Nirmatrelvir, Ritonavir, Placebo
Drug
Lead sponsor
Harlan M Krumholz
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 2, 2024 · Synced Oct 20, 2026, 1:57 PM EDT
Completed Phase 3 Interventional Results available

A Study to Compare S-217622 With Placebo in Non-Hospitalized Participants With COVID-19

NCT05305547
View directory record Official record
Conditions
SARS-CoV-2 Infection
Interventions
S-217622, Placebo
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years and older
Enrollment
2,093 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
53
States / cities
Guntersville, Alabama • Tempe, Arizona • Tucson, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 20, 2026, 1:57 PM EDT
Active, not recruiting No phase listed Observational

Post Acute Sequelae of COVID-19

NCT04964115
View directory record Official record
Conditions
Covid19, Sars-CoV-2 Infection, Dyspnea Caused by 2019-nCoV, COVID-19 Acute Respiratory Distress Syndrome, Pulmonary Fibrosis
Interventions
Cohort study
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 20, 2026, 1:57 PM EDT
Terminated No phase listed Observational

Compensatory Reserve Index (CRI) for Management of COVID-19

NCT04457817
View directory record Official record
Conditions
COVID
Interventions
CRI
Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 11, 2021 · Synced Oct 20, 2026, 1:57 PM EDT
Active, not recruiting Not applicable Interventional

HOBSCOTCH for People With Post Acute COVID-19 Syndrome (PACS)

NCT06391489
View directory record Official record
Conditions
Post Acute COVID 19 Syndrome, Memory Impairment, Memory Dysfunction, Cognitive Dysfunction
Interventions
HOBSCOTCH-PACS
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
20 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 20, 2026, 1:57 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Performance Evaluation of LumiraDx COVID-19 (SARS-CoV-2) Ag ULTRA Test

NCT05506618
View directory record Official record
Conditions
COVID-19
Interventions
Nasal Swab, Nasopharyngeal swab
Diagnostic Test
Lead sponsor
LumiraDx UK Limited
Industry
Eligibility
Not listed
Enrollment
758 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
6
States / cities
Birmingham, Alabama • Hawthorne, California • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 20, 2026, 1:57 PM EDT
Completed Phase 2 Interventional

Study of Xiflam™ Treatment in Patients Post COVID-19 Infection Suffering From What is Known as Long COVID (LC)

NCT06437223
View directory record Official record
Conditions
Long COVID
Interventions
Tonabersat, Placebo
Drug
Lead sponsor
Inflammx Therapeutics Inc
Industry
Eligibility
21 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 20, 2026, 1:57 PM EDT
Completed Phase 2 Interventional Results available

RECOVER-AUTONOMIC Platform Protocol

NCT06305780
View directory record Official record
Conditions
Long COVID, Long Covid19, Long Covid-19
Interventions
IVIG + Coordinated Care, IVIG Placebo + Coordinated Care, Ivabradine + Coordinated Care, Ivabradine Placebo + Coordinated Care, IVIG + Usual Care, IVIG Placebo + Usual Care, Ivabradine + Usual Care, Ivabradine Placebo + Usual Care
Drug
Lead sponsor
Kanecia Obie Zimmerman
Other
Eligibility
18 Years and older
Enrollment
381 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
50
States / cities
Opelika, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 45 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 20, 2026, 1:57 PM EDT
Completed No phase listed Observational

ScreenNC, a Study to Determine the Number of Asymptomatic Individuals Who Have Antibodies to the Virus That Causes COVID-19

NCT04367740
View directory record Official record
Conditions
Asymptomatic Condition, Infection Viral, Coronavirus Infections, Severe Acute Respiratory Syndrome Coronavirus 2, Coronaviridae Infections, RNA Virus Infections, Virus Diseases, Communicable Disease
Interventions
To assess for development of IgG antibodies against SARS-CoV2
Diagnostic Test
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 99 Years
Enrollment
6,313 participants
Timeline
2020 – 2022
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 9, 2023 · Synced Oct 20, 2026, 1:57 PM EDT
Terminated Phase 2 Interventional Results available

Use of Convalescent Plasma for COVID-19

NCT04408040
View directory record Official record
Conditions
COVID
Interventions
Convalescent Plasma
Biological
Lead sponsor
Northside Hospital, Inc.
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 14, 2022 · Synced Oct 20, 2026, 1:57 PM EDT
Active, not recruiting Phase 2 Interventional

The Long COVID Treatment Trial

NCT07128082
View directory record Official record
Conditions
Long COVID
Interventions
Tirzepatide, Placebo
Drug
Lead sponsor
Scripps Translational Science Institute
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 20, 2026, 1:57 PM EDT
Active, not recruiting Phase 2 Interventional

SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer

NCT04977024
View directory record Official record
Conditions
COVID-19 Infection, Hematopoietic and Lymphoid System Neoplasm, Leukemia, Lymphoma, Plasma Cell Myeloma
Interventions
COVID-19 Vaccine, Diagnostic Laboratory Biomarker Analysis, Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1
Biological · Other
Lead sponsor
GeoVax, Inc.
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
6
States / cities
Duarte, California • Baltimore, Maryland • Worcester, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Oct 20, 2026, 1:57 PM EDT